5 Robinhood Penny Stocks Gaining Momentum This Week

Penny Stock Gainers

Penny stocks trade below $5, and although they are cheap, they are nevertheless risky investments. Most of these penny stocks can be traded on platforms such as Robinhood, which permits trading with no minimum balance required and no commission fees. Robinhood penny stocks have the potential to generate significant returns, and those gains can come in a short time. It’s no surprise to see several investors rushing for Robinhood penny stocks, especially now that there is a lot of market volatility caused by COVID-19.

Interestingly, Robinhood penny stocks are ideal even for rookie traders or investors with small portfolios. Robinhood penny stocks are become increasingly popular among traders because users can trade equities and penny stocks listed on the New York Stock Exchange and the Nasdaq without commissions or hidden charges. This means 100% free trading for Robinhood penny stocks. Here are 5 Robinhood penny stocks that traders should keep an eye on:

5 Robinhood Penny Stocks Gaining Momentum: Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX)

Robinhood penny stocks

Biopharmaceutical company Catalyst Pharmaceuticals has been on the rise this month. The stock has jumped 50% since March 16 after it reported Q4 revenue results. The company reported revenue of $30.1 million, which was in line with analysts’ estimates. However, its earnings per share of $0.07 missed on analysts’ earnings estimates of $0.09 per share.

>> 4 Low Float Penny Stocks to Watch in the Last Week of March

Most of the company’s revenue was from the sales of Firdapse, which is a Lambert-Eaton myasthenic syndrome (LEMS) treatment. Catalyst Pharma is predicting sales to be between $135 million and $155 million for Firdapse in 2020. The company is also planning to expand the use of Firdapse in treating other indications.

At the time of writing, CPRX stock is up 4% at $3.97.

5 Robinhood Penny Stocks Gaining Momentum: Corpus Pharmaceuticals Holdings (NASDAQ:CRBP)

In the last two weeks, Corpus Pharmaceuticals is up around 47%. In February, the company finalized a $46 million equity financing to support its ongoing clinical trials. Currently, the company is in late-stage trials for its flagship drug candidate, lenabasum, and is in early-stage safety trials with CRB-4001.

The company is likely to provide data from key clinical trials this summer. This is good news because if the results from the late-stage trials are positive, they could catapult CRBP stock—but if negative, they could plunge it. The results will definitely be something investors want to keep an eye out for.

5 Robinhood Penny Stocks Gaining Momentum: Aurora Cannabis (TSX:ACB) (NYSE:ACB)

Robinhood penny stocks

Since March 18, when Aurora Cannabis stock hit a new low of $0.60, ACB has gained 60%. Most sectors have been hit hard this month, with the cannabis sector among the worst-hit industries.

>> More Robinhood Penny Stocks to Watch

However, Aurora’s problems began before the coronavirus crisis. Investors were concerned about its path to profitability, its management, and its debt. These problems have made it hard for Aurora to get capital, and a downward revenue projection has made investors nervous. In the past year, ACB stock has lost almost 90% of its value.

5 Robinhood Penny Stocks Gaining Momentum: Vivint Solar (NYSE:VSLR)

Vivint Solar has surged close to 50% in the past two weeks. However, this Robinhood penny stock is still 55% down from its price early this month when it reported a Q4 2019 loss of $1.02 per share against the expected per-share loss of $0.17.

Although the company reported revenue growth of 21% to $77 million, it nonetheless missed the expected revenue of $88.15 million. So far, Vivint has installed around 66 MWs, which is 22% more than last year, and its total cumulative MW installed was approximately around 1,294 MWs.

5 Robinhood Penny Stocks Gaining Momentum: Groupon Inc. (NASDAQ:GRPN)

Robinhood penny stocks

Groupon is up 98% in the past week, having previously dropped almost 70% in the last five weeks. The company’s problems were compounded by the ousting of COO Steve Krenzer and CEO Rich Williams. Groupon explained that the executives were axed from the company, and Aaron Cooper, who is Groupon’s North America President, will take over as an Interim CEO.

Even before the coronavirus, the company was in trouble after taking a beating in its Q4 earnings. Groupon missed estimates and reported serious revenue declines.

Key Takeaway

In recent weeks, there has been market turmoil, thanks to COVID-19. However, this has also created an opening for investors who are not afraid of risk. These 5 Robinhood penny stocks could be ideal because of the zero fees on the platform.

>> Read More Penny Stock News

Featured image: Pixabay

Please See Disclaimer

If You Liked This Article Click To Share

Risks and Disclosure:

Information provided in this correspondence is intended solely for informational purposes and is obtained from sources believed to be reliable. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained on this website is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions made or suggested and the actual results.

All statements and opinions expressed are the opinions of the author and not of Microsmallcap.com or its officers. The author is wholly responsible for the validity of all statements. Microsmallcap.com was not involved in any aspect of the article preparation. The author was not paid by Market Jar Media Inc for this article. The author did not pay Microsmallcap.com to publish or syndicate this article.

This article does not constitute as investment advice. Each reader is encouraged to consult with his or her individual financial advisor; any and all actions taken by a reader as a result of the information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Microsmallcap.com's terms of use and full legal disclaimer. This article is in no way a solicitation for investment. Microsmallcap.com does not render general or specific investment advice. Any information on Microsmallcap.com should not be considered a recommendation to buy or sell any security. Microsmallcap.com does not endorse or recommend the business, products, services or securities of any company mentioned on Microsmallcap.com.

Futures, stocks and options trading involves substantial risk of loss and is not suitable for every investor. The valuation of futures, stocks, and options may fluctuate, and, as a result, clients may lose more than their original investment and possibly their entire investment. Any content on this website should not be relied upon as advice or construed as providing recommendations of any kind. It is your responsibility to confirm and decide which trades to make. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

Please see our full disclaimer here for additional details before making any investment decisions.